Long-Term Real-World Effectiveness and Response Trajectories of Dupilumab in Paediatric Atopic Dermatitis
Małgorzata Ponikowska, Emilia Kucharczyk, Karol Biliński, Danuta Nowicka, Łukasz Lewandowski · 2026
Read Long-Term Real-World Effectiveness and Response Trajectories of Dupilumab in Paediatric Atopic Dermatitis by Małgorzata Ponikowska, Emilia Kucharczyk, Karol Biliński, Danuta Nowicka, Łukasz Lewandowski (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13361447.txt.
Description
Małgorzata Ponikowska and co-authors tracked a biologic drug in children with severe eczema in a 2026 study. Dupilumab is a shot that calms the immune signals driving atopic dermatitis. Long-term results in children, outside of trials, are still scarce. The team looked back at 55 young patients with moderate to severe disease treated at one center.
They followed skin scores, affected body area, and quality of life across the whole course of treatment. The main goal was the share of children reaching a 75 percent cut in a standard eczema score, and how fast that gain came. Deeper gains, safety, and how long the drug kept working were also tracked. Real-life paths show families what to expect over years, not just trial months.
Catalog record
| CREATOR | Małgorzata Ponikowska, Emilia Kucharczyk, Karol Biliński, Danuta Nowicka, Łukasz Lewandowski |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28211 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |